skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Prevention of graft rejection in allogeneic bone marrow transplantation. II. Preclinical studies with three radiation protocols

Journal Article · · Transplantation; (USA)

Three radiotherapeutic regimens were compared in vitro to determine their immunosuppressive potential against non-MHC-restricted cytotoxic cells. Assays of natural killer and lymphokine-activated killer function, and cytotoxicity against allogeneic cells were used to quantitate the cytotoxic potential of peripheral blood mononuclear cells from healthy individuals following irradiation with a single dose of 1000 cGy on day 0, 1320 cGy of fractionated radiation (165 cGy b.i.d. x 4 days), or split-dose irradiation consisting of 1000 cGy on day 0 followed 5 or 7 days later by 500 cGy. Both irradiated and nonirradiated (control) PBMC cultures were maintained in culture with medium containing interleukin-2, immunophenotyped, and assayed for cytotoxicity from 1 to 8 days after irradiation. Single dose and fractionated-dose irradiation resulted in a progressive decline in cytotoxic capacity, with an 80% inhibition of both NK and LAK cell activity 8 days after onset of irradiation. The split dose of 500 cGy administered 7 days after a dose of 1000 cGy was found to be the most effective in eliminating NK (93% inhibition) and LAK (100% inhibition) cytotoxicity. These data indicate that split-dose irradiation may result in greater immunosuppression than single-dose or fractionated irradiation.

OSTI ID:
6366870
Journal Information:
Transplantation; (USA), Vol. 50:3; ISSN 0041-1337
Country of Publication:
United States
Language:
English

Similar Records

Immunologic changes after loco-regional radiotherapy and fractionated total body irradiation (TBI) in mice
Journal Article · Fri Dec 01 00:00:00 EST 1989 · International Journal of Radiation Oncology, Biology and Physics; (USA) · OSTI ID:6366870

In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells
Journal Article · Mon Aug 01 00:00:00 EDT 1988 · Cell. Immunol.; (United States) · OSTI ID:6366870

Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells
Journal Article · Thu Nov 01 00:00:00 EST 1990 · Journal of Clinical Immunology; (USA) · OSTI ID:6366870